# Epidiolex® for Anxiety in Pediatric Epilepsy

> **NCT05324449** · PHASE4 · COMPLETED · sponsor: **Hugo W. Moser Research Institute at Kennedy Krieger, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Anxiety
- Epilepsy

## Interventions

- **DRUG:** Cannabidiol 100 MG/ML

## Key facts

- **NCT ID:** NCT05324449
- **Lead sponsor:** Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-05
- **Primary completion:** 2025-03-17
- **Final completion:** 2025-05-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05324449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05324449, "Epidiolex® for Anxiety in Pediatric Epilepsy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05324449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*